Novelcare · Jul 2026
Official page describing practice-side benefits, including up to $50-$200 per eligibility review, patient follow-up reminders, branded patient awareness kits, and patient-progress updates.
Empowering every doctor and every patient to participate in research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Novelcare is a New York-based, remote healthcare technology company that helps physicians and clinics identify local, medically relevant clinical trial opportunities for patients and route study information into normal clinical workflows. The company presents itself as a free-to-start study access / provider activation platform with HIPAA/BAA-first data handling and limited paid chart-review workflows.
Primary product
Study Access Program / clinical trial matching platform for providers
Founded
2022
Headquarters
New York City, NY, USA
Team size
1-10
Work style
Remote
Industry
Hospitals and Health Care
Sub-industry
Healthcare technology; clinical trial matching / provider activation
Offices
Business model
Stage
Seed
Total raised
$500K
Latest round
Seed · Jan 2023
Latest amount
$500K
Jan 2023 · Y Combinator
Leadership
Ethan Bond
Co-founder and CEO
Co-founder & CTO
Head of Growth Operations
Head of Clinical Operations
Investors
Public materials describe a small geo-distributed team of clinicians, technologists, designers, and operations experts. The company emphasizes trust, alignment, thoughtful design, clear boundaries, shared purpose, and minimal disruption to clinical workflows.
Work style
Remote
Compensation
No public employee compensation data was found. Public compensation signals are mostly provider-side: the company says it is free for most practices, may charge $100 per month per provider for practices serving more than 1 million patients, and may pay providers up to $50-$200 per eligibility review / up to $200 per chart review on some studies.
Pricing
Free for most community practices; $100 per month per provider for practices serving more than 1 million patients; trial sites pay only for randomizations and the service is free if invited by a sponsor; paid chart-review / eligibility-review compensation is offered in some workflows.
Differentiators
Technology
Customers
Competitors
Novelcare · Jul 2026
Official page describing practice-side benefits, including up to $50-$200 per eligibility review, patient follow-up reminders, branded patient awareness kits, and patient-progress updates.
Novelcare Blog · Jan 2025
Ethan Bond discusses DPC economics and argues that Novelcare can fit independent practices with zero workflow disruption while integrating clinical studies into care.
Novelcare Blog · Dec 2024
Blog post connects medication affordability to clinical trials and reiterates Novelcare's EMR-integrated clinical trial matching model.
aVenture · Mar 2024
Third-party company research page states Novelcare/SelectIQ is a YC W23 seed company, founded in 2022, with a $500k seed round closed in January 2023.